Research programme: stem cell-based therapeutics - ViaCyte

Drug Profile

Research programme: stem cell-based therapeutics - ViaCyte

Alternative Names: PEC-01™; PEC-QT™; Stem cell-derived pancreatic progenitor cells - ViaCyte

Latest Information Update: 23 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BetaLogics; ViaCyte Inc
  • Developer University of California at San Francisco; ViaCyte Inc
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 17 Apr 2018 Viacyte has patent protection for Stem Cell-Derived Cell Replacement Therapies in Europe, USA, Japan, China, Hong Kong, Singapore, South Korea and Australia
  • 17 Apr 2018 Preclinical trials in Type-2 diabetes mellitus in USA (Parenteral)
  • 29 Mar 2017 ViaCyte and W. L. Gore & Associates collaborate to develop novel implantable delivery technologies for cell therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top